{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T16:46:03Z","timestamp":1764175563599,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T00:00:00Z","timestamp":1705104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP2001396"],"award-info":[{"award-number":["APP2001396"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.nano.2024.102733","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T02:31:34Z","timestamp":1704681094000},"page":"102733","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A PEGylated liposomal formulation of prochlorperazine that limits brain exposure but retains dynamin II activity: A potential adjuvant therapy for cancer patients receiving chemotherapeutic mAbs"],"prefix":"10.1016","volume":"56","author":[{"given":"Christopher N.","family":"Subasic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney F.","family":"Minchin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Kaminskas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2024.102733_bb0005","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","article-title":"Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies","volume":"180","author":"Chew","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.nano.2024.102733_bb0010","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/19024","article-title":"Impairment of dynamin's GAP domain stimulates receptor-mediated endocytosis","volume":"398","author":"Sever","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.nano.2024.102733_bb0015","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1111\/tra.12272","article-title":"Phenothiazine-derived antipsychotic drugs inhibit dynamin and clathrin-mediated endocytosis","volume":"16","author":"Daniel","year":"2015","journal-title":"Traffic"},{"key":"10.1016\/j.nano.2024.102733_bb0020","series-title":"StatPearls","article-title":"Antipsychotic medications","author":"Chokhawala","year":"2023"},{"key":"10.1016\/j.nano.2024.102733_bb0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1080\/14686996.2019.1590126","article-title":"Toxicity and immunogenicity concerns related to PEGylated-micelle carrier systems: a review","volume":"20","author":"Shiraishi","year":"2019","journal-title":"Sci Technol Adv Mater"},{"key":"10.1016\/j.nano.2024.102733_bb0030","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYXTM\/Doxil\u00ae) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nano.2024.102733_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23040907","article-title":"Liposomal drug delivery systems and anticancer drugs","volume":"23","author":"Olusanya","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.nano.2024.102733_bb0040","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/jphp.13098","article-title":"An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites","volume":"71","author":"Attia","year":"2019","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.nano.2024.102733_bb0045","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.2217\/nnm-2018-0478","article-title":"Drug formulation and nanomedicine approaches to targeting lymphatic cancer metastases","volume":"14","author":"Wang","year":"2019","journal-title":"Nanomedicine (Lond)"},{"key":"10.1016\/j.nano.2024.102733_bb0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/jpet.103.059535","article-title":"Direct 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies","volume":"308","author":"Bao","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2024.102733_bb0055","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0005-2736(95)00121-I","article-title":"The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery","volume":"1238","author":"Webb","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.nano.2024.102733_bb0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/labinvest.2010.131","article-title":"Tumor-initiating activity and tumor morphology of HNSCC is modulated by interactions between clonal variants within the tumor","volume":"90","author":"Cameron","year":"2010","journal-title":"Lab Invest"},{"key":"10.1016\/j.nano.2024.102733_bb0065","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2021.07.006","article-title":"The pharmacokinetics of PEGylated liposomal doxorubicin are not significantly affected by sex in rats or humans, but may be affected by immune dysfunction","volume":"337","author":"Subasic","year":"2021","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2024.102733_bb0070","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1073\/pnas.161274798","article-title":"Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease","volume":"98","author":"Korth","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.nano.2024.102733_bb0075","first-page":"23","article-title":"Disposition of ethopropazine enantiomers in the rat: tissue distribution and plasma protein binding","volume":"2","author":"Brocks","year":"1999","journal-title":"J Pharm Pharm Sci"},{"key":"10.1016\/j.nano.2024.102733_bb0080","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-5347(25)00369-6","article-title":"Comparative study of phenothiazine derivatives on monoamine metabolism\u2013direct correlation between the concentrations of drugs and monoamine metabolites in the brain","volume":"240","author":"Shibanoki","year":"1987","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.nano.2024.102733_bb0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jconrel.2014.03.012","article-title":"Pulmonary administration of a doxorubicin-conjugated dendrimer enhances drug exposure to lung metastases and improves cancer therapy","volume":"183","author":"Kaminskas","year":"2014","journal-title":"J Control Release"},{"key":"10.1016\/j.nano.2024.102733_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpb.2018.01.001","article-title":"A comparison of the lung clearance kinetics of solid lipid nanoparticles and liposomes by following the 3H-labelled structural lipids after pulmonary delivery in rats","volume":"125","author":"Haque","year":"2018","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.nano.2024.102733_bb0095","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0005-2736(96)00197-6","article-title":"Role of membrane lipid distribution in chlorpromazine-induced shape change of human erythrocytes","volume":"1323","author":"Chen","year":"1997","journal-title":"Biochim Biophys Acta Biomembranes"},{"key":"10.1016\/j.nano.2024.102733_bb0100","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1128\/AAC.02593-12","article-title":"Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes","volume":"57","author":"Chamoun-Emanuelli","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.nano.2024.102733_bb0105","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1073\/pnas.1324135111","article-title":"Remote loading of preencapsulated drugs into stealth liposomes","volume":"111","author":"Sur","year":"2014","journal-title":"Proc Natl Acad Sci"},{"key":"10.1016\/j.nano.2024.102733_bb0110","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3389\/fonc.2015.00115","article-title":"Tumor interstitial fluid formation, characterization, and clinical implications","volume":"5","author":"Wagner","year":"2015","journal-title":"Front Oncol"},{"key":"10.1016\/j.nano.2024.102733_bb0115","doi-asserted-by":"crossref","first-page":"735","DOI":"10.2147\/IJN.S55805","article-title":"Comparison of in vitro dialysis release methods of loperamide-encapsulated liposomal gel for topical drug delivery","volume":"9","author":"Hua","year":"2014","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2024.102733_bb0120","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0378-5173(03)00262-X","article-title":"Characterisation of drug release from cubosomes using the pressure ultrafiltration method","volume":"260","author":"Boyd","year":"2003","journal-title":"Int J Pharm"},{"key":"10.1016\/j.nano.2024.102733_bb0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/jat.4046","article-title":"In vitro anticancer activity of fluphenazine, perphenazine and prochlorperazine. A review","volume":"41","author":"Otr\u0119ba","year":"2021","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.nano.2024.102733_bb0130","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/0006-2952(83)90019-9","article-title":"Binding of phenothiazine neuroleptics to plasma proteins","volume":"32","author":"Verbeeck","year":"1983","journal-title":"Biochem Pharmacol"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T07:19:54Z","timestamp":1761549594000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963424000029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":26,"alternative-id":["S1549963424000029"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2024.102733","relation":{},"ISSN":["1549-9634"],"issn-type":[{"type":"print","value":"1549-9634"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A PEGylated liposomal formulation of prochlorperazine that limits brain exposure but retains dynamin II activity: A potential adjuvant therapy for cancer patients receiving chemotherapeutic mAbs","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2024.102733","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102733"}}